Ketamina en el manejo del dolor refractario por cáncer

Autores/as

  • Karla Vargas Rumoroso Centro Nacional de Control del Dolor y Cuidados Paliativos
  • Isaias Salas Herrera Centro Nacional de Control del Dolor y Cuidados Paliativos

DOI:

https://doi.org/10.51481/amc.v48i2.242

Palabras clave:

dolor, cáncer, analgesia, ketamina

Resumen

Los pacientes con cáncer presentan dolor en el rango entre moderado e intenso durante el transcurso de su enfermedad, principalmente en la etapa terminal. La escalera analgésica de la Organización Mundial de la Salud (OMS) se ha empleado como guía terapéutica para tratar a estos pacientes; utiliza tres grupos de fármacos: opiáceos, antiinflamatorios no esteroideos (AINES) y coadyuvantes. Dentro de estos últimos se encuentra la ketamina, un derivado fenciclidínico que interactúa con los receptores N-metil-D-aspartato (NMDA). Tradicionalmente ha sido utilizado como inductor de la anestesia general, y en dosis subanestésicas se emplea para el tratamiento del dolor refractario al uso de opioides.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Organización Mundial de la Salud. National cancer control pro-grammes: policies and manage trial guidelines. Ginebra, 2002.

Organización Mundial de la Salud. Adherencia a los tratamientos alargo plazo: pruebas para la acción. Ginebra, 2003.

Fine P. Low-dose ketamine in the management of opioid resistantterminal cancer pain. J Pain Symptom Manage. 1999;17:296-300.

Patterson D, Shahar S. Burn pain. In: Loeser J, et al., editors.Bonica’s management of pain. Philadelphia: Lippincott, Williams andWilkins; 2001. pp. 781–7.

Weinbroum A. A single small dose of postoperative ketamine pro-vides rapid and sustained improvement in morphine analgesia in thepresence of morphine resistant pain. Anesth Analg. 2003;96:789-95.

Bell R, Dahl J, Moore R, Kalso E. Peri-operative ketamine for acutepost-operative pain: a quantitative and qualitative systematic reviewActa Anaesthesiol Scand. 2005;49:1405-28.

Kafali H, Aldemir B, Kaygusuz K, Gursoy S, Kunt N. Small-doseketamine decreases postoperative morphine requirements. Eur JAnaesthesiol. 2004 Nov;21:916-7.

Fine P. Ketamine: From Anesthesia to Palliative Care. AAHPMBulletin 2003, 3: 1-6.

Richebe P, Rivat C, Laulin JP, Maurette P, Simonnet G. Ketamineimproves the management of exaggerated postoperative painobserved in perioperative fentanyl-treated rats. Anesthesiology.2005;102:421-8.

Jackson K, Ashby M, Martin P.: “Burst” Ketamine for refractory can-cer pain: an open-label audit of 39 patients. J Pain Symptom Manage2001; 22: 834-42.

Pasero C, McCaffery M. Pain control: ketamine: low doses may pro-vide relief for some painful conditions. Am J Nurs. 2005;105:60-4.

Langsjo J, Maksimow A, Salmi E, Kaisti K, Aalto S, Oikonen V,Hinkka S, Aantaa R, Sipila H, Viljanen T, Parkkola R, Scheinin H. S-ketamine anesthesia increases cerebral blood flow in excess of themetabolic needs in humans. Anesthesiology. 2005 ;103:258-68.

Shimoyama M, Shimoyama N, Gorman A, Elliot R, Inturrici C. OralKetamine is antinociceptive in the rat: the role of norketamine. Pain1999; 81: 85-93.

Krystal J, Karper L, Benett A. Interactive effects of subanestetic ket-amine and subhypnotic lorazepam in humans. Psichopharmacology1998; 38: 203-19.

Fisher K, Coderre T, Hagen N. Targeting the N-Methyl-D-Aspartatereceptor for chronic pain management: preclinical animal studies,recent clinical experience and future research directions. J PainSymptom Manage 2000; 20:358-73.

Annetta M, Iemma D, Garisto C, Tafani C, Proietti R. Ketamine: newindications for an old drug. Curr Drug Targets. 2005;6:789-94.

Lynch M, Clark A, Sawynok J, Sullivan M. Topical amitriptyline andketamine in neuropathic pain syndromes: an open-label study. J Pain.2005; 6:644-9.

Reves J, et al. Intravenous nonopioid anesthetics. In: Miller R, editor.Miller’s anesthesia. Philadelphia: Hanley and Belfus; 2005. p.317–78.

Larcher A, Laulin J, Celerier E, Le Moal M, Simonnet G. Acutetolerance associated with a single opiate administration: involvementof N-methyl-D-aspartate-dependent pain facilitatory systems.Neuroscience 1998; 84:583-9.

Akin Takmaz S, Inan N, Gunal S, Kaymak C, Sakalli M, Dikmen B.Ketamine combined with morphine for the management of cancerpain in a patient with meperidine tolerance and addiction. Agri. 2005Jul;17:44-7.

Anghelescu DL, Oakes LL. Ketamine use for reduction of opioid tol-erance in a 5-year-old girl with end-stage abdominal neuroblastoma.J Pain Symptom Manage. 2005;30:1-3.

Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvantfor severe pain: development and retrospective audit of a protocol fora palliative care unit. J Palliat Med. 2005;8:49-57.

Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketaminefor intractable cancer pain. Support Care Cancer. 2005;13:188-93.

Slatkin NE, Rhiner M. Ketamine in the treatment of refractory cancerpain: case report, rationale, and methodology. J Support Oncol.2003;1:287-93.

Kotlinska-Lemieszek A, Luczak J. Subanesthetic ketamine: an essen-tial adjuvant for intractable cancer pain. J Pain Symptom Manage.2004;28:100-2.

Rae F, Eccleston C, Kalso E. Ketamine as adjuvant to opioids forcancer pain. A Qualitative Systematic Review. J Pain SymptomManage 2003; 26:867-875.64Figura 1. Receptor NMDA. Modificado de www.SNCforum.com

Thogulava R, Saxena A., Sushma B. Oral Ketamine as an adjuvant tooral morphine for neuropathic pain in cancer patients. J PainSymptom Manage. 2002;23:60-65

Kannan T. Oral ketamine as an adjuvant to oral morphine for neuro-pathic pain in cancer patients. J Pain Symptom Manage2002;23:60–5.

Friedman R., Li V., Keuppers F., Atkinson G. Oral Ketamine in hepa-tocellular carcinoma. Pain medicine 2000; 1: 181-182.

McDonnell F., Sloan J., Hamann S: Advances in cancer pain manage-ment. Current Pain Headache Rep 5: 265-71, 2001.

Ban C,Tsui H, Dawn D, Sunil D, Malherbe S, Intravenous KetamineInfusion as an Adjuvant to Morphine in a 2-Year-Old With SevereCancer Pain From Metastatic Neuroblastoma. J Pediatr HematolOncol. 2004;26:678–680.

Mercadante S, Arcuri E, Tirelli W. Analgesic Effect of IntravenousKetamine in Cancer Patients on Morphine Therapy: A Randomized,Controlled, Double-Blind, Crossover, Double-Dose Study. J PainSymptom Manage. 2000; 20:246-252.

Yang C, Wong C, Chang J. Intrathecal ketamine reduces morphinerequirements in patients with terminal cancer pain. Canadian J ofAnaesthesia 1996; 43:379-83.

Carr D, Goudas L, Denmana W, BroOkoff D, Staats P, BrennenL,Green G, Albine R, Hamilton D, Rogers M, Firestone L, Alvin R,Mermelstein F. Safety and efficacy of intranasal ketamine for thetreatment of breakthrough pain in patients with chronic pain: a ran-domized,double-blind, placebo-controlled, crossover study. Pain2004;108: 17–27.

Gammaitoni A, Gallagher R, Welz-Bosna M. Topical ketamine gel:possible role in treating neuropathic pain. Pain Med. 2000;1:97-100.

Yaster M. General anesthesia. In: Yaster M, et al., editors. Pediatricpain management and sedation handbook. St. Louis: Mosby-Yearbook; 1997. p. 376.

Descargas

Publicado

2006-04-01

Cómo citar

Vargas Rumoroso, K., & Salas Herrera, I. (2006). Ketamina en el manejo del dolor refractario por cáncer. Acta Médica Costarricense, 48(2), 61–65. https://doi.org/10.51481/amc.v48i2.242

Artículos similares

También puede {advancedSearchLink} para este artículo.